Acquisition of Astria Therapeutics, Inc. (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Total Consideration Transferred and Allocation to Assets and Liabilities

The following is a summary of the total consideration transferred and allocation of consideration transferred to the assets acquired, liabilities assumed, and IPR&D – navenibart in connection with the Merger:


Equity consideration1	$	251,655
Cash consideration	608,633
Direct transaction costs	14,025
Total purchase price	$	874,313

Assets acquired and liabilities assumed:
Cash and cash equivalents	$	130,588
Short-term investments	63,033
Trade receivables	1,980
Prepaid expenses and other current assets	5,547
Property and equipment	642
Other assets	14,417
Right of use asset	4,198
IPR&D - navenibart	705,267
Assembled workforce	600
Accounts payable	(22,627)
Accrued expenses	(10,146)
Operating lease liabilities, current	(1,249)
Deferred revenue, current	(4,598)
Operating lease liabilities, net of current portion	(2,949)
Deferred revenue, net of current portion	(10,390)
Net assets acquired	$	874,313
1 Consists of the issuance of 37,282 shares of the Company’s common stock multiplied by the Company’s common stock closing price of $6.75 per share on January 22, 2026.

Schedule of Accrued Liability Activity Under Separation Agreements

The following table summarizes the accrued liability activity recorded in connection with the separation agreements for the six months ended June 30, 2026:


Balance at December 31, 2025	$	—
Workforce reduction expense recorded during the three months ended March 31, 2026	11,927
Amounts paid during the three months ended March 31, 2026	(2,871)
Balance at March 31, 2026	$	9,056
Amounts paid during the three months ended June 30, 2026	(3,900)
Balance at June 30, 2026	$	5,156